[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622325":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":32,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"patients aged ≥ 18 years who have undergone coronary angioplasty for DES restenosis",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Gabriele Ghetti, MD","CONTACT","+39 0512144475","gabriele.ghetti@aosp.bo.it",[18],{"facility":19,"status":10,"city":20,"state":10,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"IRCCS Policlinico di Sant'Orsola","Bologna","40138","Italy","IT",{"type":25,"coordinates":26},"Point",[27,28],11.33875,44.49381,{"lat":28,"lon":27},[31],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100622325","target-vessel-failure-after-laser-assisted-percutaneous-angioplasty-versus-balloon-based-treatment-for-drug-eluting-in-stent-restenosis-100622325",false,"NCT07382154","Target Vessel Failure After Laser Assisted Percutaneous Angioplasty Versus Balloon-based Treatment for Drug Eluting In-stent Restenosis","SONIC","Inclusion Criteria:\n\n* Patients aged ≥ 18 years who have undergone coronary angioplasty for restenosis of a drug-eluting stent in at least one coronary vessel\n* Acquisition of written informed consent from patients included in the study\n* 1-year follow-up in patients in the retrospective cohort\n\nExclusion Criteria:\n\n* concurrent presence of a new angiographically significant lesion on the coronary artery treated for ISR\n* hybrid treatment of two or more drug-eluting stent restenoses in the same angioplasty procedure. That is, treatment of one or more restenoses with balloon-based therapy alone and treatment of one or more restenoses using the ELCA technique in the same angioplasty procedure.\n* inability to take dual antiplatelet therapy for the period required by the coronary angioplasty procedure 4) life expectancy \\\u003C 1 year","ALL","19 Years",{"count":44,"type":45},1260,"ESTIMATED","OBSERVATIONAL","Stent restenosis (ISR) is an increasingly common problem; in fact, approximately 10% of coronary angioplasty procedures involve the treatment of a previously implanted stent. In cases of ISR of drug-eluting stents, the rate of further restenosis remains high (approximately 13% at one year). The treatment of stent restenosis consists of the use of balloon-based methods. Some small, single-center observational studies suggest the effectiveness of Excimer Laser Coronary Atherectomy (ELCA) in this context, allowing for a wider coronary lumen, a better minimum stent area (MSA), and a numerically lower incidence of new stent restenosis.\n\nDemonstrating that Excimer Laser Coronary Atherectomy (ELCA)-assisted angioplasty treatment for DES ISR is associated with a lower incidence of Target Vessel Failure at 1 year compared to balloon-based angioplasty techniques may allow for better treatment of this type of patient.",[49],"In-stent Restenosis",[51,52,53],"in-stent restenosis","drug-eluting stents","Excimer Laser Coronary Atherectomy","NOT_YET_RECRUITING","2026-01-26",{"date":57,"type":58},"2026-02-02","ACTUAL",{"date":60,"type":45},"2026-02",{"date":62,"type":45},"2028-07",{"name":5,"class":6},1]